A 73-year-old woman presented with a pancreas divisum was admitted for acute pancreatitis. Abdominal CT was performed due to a torpid evolution with fever and oral intolerance, demonstrating necrosis and ductal disruption in the pancreatic neck. An ERCP was attempted, however, the minor papilla (MP) could not be identified because of the presence of edematous duodenal folds. EUS revealed ductal disruption and the pancreatic duct was punctured using a 22G needle at the level of the body-tail junction (<2 mm). Then, rendez-vous was completed by cannulating the MP with a rail technique and a pancreatic stent was placed. Given the persistence of oral intolerance secondary to the duodenal parietal inflammatory component, EUS-guided gastrojejunostomy was performed with a 20 mm luminal apposition stent. The patient exhibited progressive clinical improvement and was discharged following a control ERCP, which confirmed resolution of the ductal disruption and significant improvement of the duodenal inflammatory changes. Consequently, the endoscopic gastrojejunostomy was reversed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.17235/reed.2025.11124/2025 | DOI Listing |
A 73-year-old woman presented with a pancreas divisum was admitted for acute pancreatitis. Abdominal CT was performed due to a torpid evolution with fever and oral intolerance, demonstrating necrosis and ductal disruption in the pancreatic neck. An ERCP was attempted, however, the minor papilla (MP) could not be identified because of the presence of edematous duodenal folds.
View Article and Find Full Text PDFUnlabelled: Oncogenic KRAS mutations underlie some of the deadliest human cancers. Genetic or pharmacological inactivation of mutant KRAS is not sufficient for long-term control of advanced tumors. Using a conceptual framework of pancreatic ductal adenocarcinoma, we find that CRISPR-mediated ablation of mutant KRAS can terminate tumor progression contingent on the concomitant inactivation of STAT3.
View Article and Find Full Text PDFCell Death Dis
March 2025
Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis, largely due to the rapid development of chemoresistance in patients. Mitochondrial dynamics play a crucial role in cancer cell survival. Currently, the specific mechanisms underlying gemcitabine resistance in PDAC remain unknown.
View Article and Find Full Text PDFJ Nanobiotechnology
March 2025
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, M5G 1L7, Canada.
Radiotherapy is a leading method for cancer treatment, effectively eliminating cancer cells but often causing collateral damage to surrounding healthy tissue. Radiosensitizers aim to enhance the therapeutic effects of radiotherapy while minimizing harm to normal cells. We recently reported atomically-precise gold nanoclusters, Au(Lys-Cys-Lys), synthesized via a photochemical method coupled with a novel accelerated size-focusing procedure.
View Article and Find Full Text PDFAnn Surg Oncol
March 2025
Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: The combination of pembrolizumab with neoadjuvant chemotherapy (NAC) for triple-negative breast cancer (TNBC) improves pathologic complete response (pCR) rates and event-free survival. Yet it is unclear which patients benefit most from the addition of immunotherapy. This study aims to identify predictive factors for pCR in patients with TNBC receiving chemo-immunotherapy (chemo-IO).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!